During recent years it has been shown that the anesthetic drug etomidate is also a potent adrenostatic agent [2, 3, 5, 7, 8, 12, 13, 17, 19] . Etomidate blocks the cytochrome P450-dependent adrenal enzymes 11/q-hydroxylase and cholesterol-side-chain cleavage enzyme [3, 5, 8, 12, 19] . Using dispersed guinea-pig adrenal cells, etomidate has been proved to be the most powerful adrenostatic drug available [13] . In this system a mean etomidate concentration of 97 nmol/1 was required for 50% inhibition of cortisol secretion [I 3] . This is considerably lower than the target mean plasma concentration of 560 nmol/l to induce sedation [10] . Accordingly after a single induction dose of etomidate (0.3 mg/kg body weight) the adrenocortical blockade lasts several hours [2, 7] , while the hypnotic action of etomidate rapidly fades. Using low plasma concentrations it should, therefore, be possible to dissociate the adrenostatic action of etomidate from the hypnotic properties of the compound. This was successfully demonstrated in a small number of normal subjects by Engelhardt et al. [6] using a bolus dose of 0.03 mg/kg body weight followed by a continuous infusion of etomidate at a dose of 0.3 mg/kg/h.
The aim of the present study was to evaluate the adrenostatic potential of low-dose nonhypnotic etomidate in the treatment of patients with Cushing's syndrome. The efficacy of hypnotic doses of etomidate in reversing hypercortisolemia has been proved recently [9] .
Patients and Methods
A total of six patients with Cushing's syndrome was studied (1 male, 5 females, aged 37 to 54 years). Cushing's syndrome was diagnosed by dexamethasone nonsuppressible serum cortisol, ele- Table I .
Protocol:
The patients were studied during 3 consecutive days. On day i placebo (0.9% saline) was given intravenously over 8 h. On day 2 a continuous infusion of etomidate (2.5 mg/h) was started at 8:00 h and continued until 16:00 h of day 3 (infusion period 32 h; n = 5). In addition, in three patients ACTH stimulation tests (250 gg 1-24 ACTH as bolus dose intravenously) were performed at 15:00 h on the 3 consecutive days. Three patients underwent a similar protocol with the dose of etomidate increased to 0.3 mg/kg/ h. In case of hypnotic side effects the dose ofetomidate was reduced by 50%.
Blood samples were collected in hourly intervals from 8: 00 h until 16: 00 h during the 3 days of the study. Serum cortisol and 1 l-deoxycortisol were measured by radioimmunoassay using commercially available reagents (NEN, Dreieich, DRG Instruments, Marburg, FRG), plasma ACTH was determined by radioimmunoassay [i] after extraction with QUSO G32 [18] .
Statistical evaluation was performed using Student's t-test for paired data. 
Results
Baseline serum cortisol concentrations ranged between 22.0 and 106.3 I~g/dl, with tke highest concentrations in the patient with ectopic ACTH secretion due to a :medullary carcinoma of the thyroid. As expected, no change in serum cortisol levels was observed during administration of saline. After commencing low dose etomidate (2.5 rag/h) a continuous fall of serum cortisol was observed in all subjects from a mean of 39.4_+13.3 to 21.1 _+5.7 gg/dl (2_+ SEM) at 1500 h (P<0.05). On day 3 serum cortisol was reduced further to 12.3_+5.7 ~tg/dl at 8:00h (P<0.05 compared to placebo) and remained unchanged during the rest of the infusion period, indicating that steadystate conditions had been reached (Fig. 1) . Stimulation with ACTH induced an increase in serum cortisol of 28.6 ± 7.9 gg/dl during placebo, which was not influenced by an 8-h infusion of etomidate (A cortisol: 28.5-+8.3 pg/dl). However, on day 3 at the end of the infusion period the cortisol in- crease after ACTH was diminished to 13.6 _+ 3.9 Ixg/ dl (Fig. 1) .
The pattern of the cortisol response to etomidate was very similar when an initial dose of 0.3mg/kg/h was used with a decline from 72.1 +30.4 gg/dl to 29.3_+8.3 I.tg/dl at 15:00 h after the start of etomidate and steady-state concentrations of 11.2-+ 2.4 gg/dl on day 3 (Fig. 2) . However, in contrast to a dose of 2.5 mg/h, the higher dose of etomidate completely blocked the cortisol response to exogenous ACTH (Fig. 2) . During administration of 0.3 mg/kg/h etomidate a slight sedation was noticed in two of the three patients, which rapidly disappeared after reduction to 0.15 mg/kg/h. Basal plasma ACTH concentrations ranged from undetectable (in the patient with bilateral adrenal adenoma) to 358 pg/ml. No consistent change of plasma ACTH concentrations was observed in any single patient, in particular no ACTH increase was demonstrated in the three patients with Cushing's disease.
Baseline serum l l-deoxycortisol concentrations ranged from 3.8 to 18.3 ng/ml during placebo and consistently increased during etomidate infusion to a variable extent reaching maximum values between 75 ng/ml (adrenal adenoma) and 452 ng/ ml (ectopic ACTH syndrome). During 2.5 mg etomidate/h 11-deoxycortisol rose from 9.1 +2.9 rig/ ml at 8:00 h of day 2 to 125-+68 ng/mt at 15:00 h of day 3.
Discussion
In this study etomidate was successfully employed to correct the hypercortisolemia of Cushing's syndrome without unwarranted hypnotic side effects. Independent of baseline levels cortisol was suppressed to within the normal range with as little as 2.5 mg/h etomidate. Although the cortisol response to exogenous ACTH was not completely blocked at this dose, no escape of serum cortisol was found, as no increase in endogenous ACTH secretion occurred.
A failure of ACTH to rise in response to adrenostatic therapy in Cushing's disease has also been observed during administration of ketoconazole, another imidazole derivative [14] , as well as during long-term treatment with metyrapone and aminoglutethimide [111. This phenomenon probably reflects the autonomous nature of ACTH secretion by the pituitary tumor, rather than a direct suppressive action of these substances at the pituitary level [15] .
When etomidate was given in a dose of 0.3 mg/ kg/h, responsiveness of cortisol to exogenous ACTH was rapidly lost, making this dosage at first glance even more attractive for control of hypercortisolemia. However, in contrast to the findings of Engelhardt et al. [6] in normal subjects, sedation was observed in two of the three patients studied. Thus, at this dose only a small margin separates the adrenostatic action of etomidate from its potent hypnotic properties. This was amply demonstrated in another patient with an adrenal adenoma in whom incorrect handling of the more highly concentrated etomidate solution led to a short period of deep sedation. Moreover, for infusion ofetomidate at a dose of 0.3 mg/kg/h a special preparation of etomidate dissolved in ethanol is necessary, which was introduced only for investigational use in long-term sedation and is not generally available. These difficulties and the observation that steady-state concentrations of cortisol during infusion with etomidate were rather similar with the two different dosages make 0.3 mg/kg/h etomidate less suitable for treatment of hypercortisolemia.
Etomidate for induction of anesthesia is dissolved in propyleneglycol. Because of possible hematolytic side effects of this solvent, no more than 80 mg of etomidate should be administered within 24 h according to the guidelines of the manufacturer. Given as a continuous infusion this equals a dose of 3.3 mg/h, which is 33% higher than the dose successfully used in our study. Thus, the wider margin of safety and the availability suggest that a dose of 80 rag/24 h (0.04-0.05 mg/kg/h) should be infused for rapid correction of hypercortisolemia in Cushing's syndrome.
Adrenostatic therapy of Cushing's syndrome is of limited value as in this disease surgical removal of the underlying cause is the ultimate therapeutic goal. However, long-term treatment with adrenostatic agents has been shown to be feasible in a number of studies [4, 11, 13, 16] and may be the treatment of choice for ectopic Cushing's syndrome in the presence of extensive disease [16] . Moreover, clinical improvement achieved by adrenostatic agents may favorably influence the results of later surgery. In the severely ill patient with Cushing's syndrome, rapid control of hypercortisotemia may be mandatory to avoid serious complications due to hypokalemia or psychosis and, thus, be a prerequisite for further management. Here etomidate may become the drug of choice because it is the only adrenostatic agent which can be administered intravenously while lacking the side effects frequently encountered with other adrenostatic agents.
In conclusion, low-dose etomidate has been shown to correct the hypercortisolemia of Cushing's syndrome without hypnotic side effects. As etomidate is the only adrenostatic agent which can be given intravenously it appears to be especially suitable for the initial therapy of the severely ill patient with Cushing's syndrome, in a therapeutic dose of 0.04-0.05 mg/kg/h.
